Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | RAB11FIP3 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | ACAA2 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | ZYG11B | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | CSTF1 | CTRPv2 | pan-cancer | AAC | -0.13 | 5e-05 |
mRNA | MYT1L | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | HNRNPD | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |
mRNA | HAUS1 | CTRPv2 | pan-cancer | AAC | 0.13 | 5e-05 |
mRNA | ATP6V1E1 | CTRPv2 | pan-cancer | AAC | -0.14 | 5e-05 |
mRNA | GALE | CTRPv2 | pan-cancer | AAC | -0.14 | 5e-05 |
mRNA | ZNF24 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |